Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinsons disease which is currently in early-stage clinical testing.
The FDA designation allows for benefits such as more frequent meetings and communication with the regulator during clinical development, and a truncated six-month review time.
Those are all considerations for the future as the first patients only started to be treated with DA01 in a phase 1 trial aimed primarily at showing the safety of the therapy, which is trying to replenish the dopaminergic neurons that progressively die away in Parkinsons and lead to slow, laboured movement, tremors and other symptoms.
The therapy involves implantation of dopamine-producing cells under general anaesthesia into a part of the brain called the putamen, which is particularly affected by neuron loss in Parkinsons and is responsible for regulating movement as well as some types of learning.
Patients take immune-suppressing drugs to prevent their body rejecting the transplanted cells, and the safety and tolerability of the procedure as well as the ability of the transplant to survive will be monitored for two years.
BlueRock is also hoping to demonstrate some evidence of efficacy, and will look at clinical measures such as motor function over the same time period. It is the first trial in the US to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinsons, according to the company.
The first patient in the trial, which will eventually enrol 10 subjects with advanced Parkinsons, was treated at Memorial Sloan Kettering Cancer Centre in June, and others will be recruited at Weill Cornell Medical Centre, the University of California, Irvine, and the University of Toronto.
Our objective is to use authentic cells, to have them integrate entirely into the brain and restore lost physiologic function, said BlueRock chief executive Emile Nuwaysir, as the first patient was treated.
If successful, this new therapeutic modality could have implications for the Parkinsons community and beyond, he added.
Bayer took control of BlueRock in 2019, three years after backing the formation of the company as joint venture with private equity group Versant, in a deal that valued the biotech at $1 billion.
DA01 is Bluerocks lead cell therapy programme, but the company is also working on treatments for other neurological disorders, degenerative heart disease, and autoimmune disorders.
Bayer is also developing a gene therapy for Parkinsons originated by Asklepios Bio (AskBio), which it acquired for $2 billion upfront last year with another $2 billion tied to milestones, and has pledged to make cell and gene therapies a pillar of its R&D strategy.
Read more here:
- Cellino is using AI and machine learning to scale production of stem cell therapies - TechCrunch - September 22nd, 2021
- Capping Medicare Part B payments will limit outpatient access to CAR-T - STAT - September 22nd, 2021
- Treating Patients with High-Risk Myelodysplastic Syndrome - Targeted Oncology - September 22nd, 2021
- FDA Issues Draft Guidance on Donor Eligibility and Manufacturing of Cellular Therapies for Animals | FDA - FDA.gov - September 22nd, 2021
- CD19 As a Targeted Agent in CAR T Cell Therapy for R/R DLBCL - Targeted Oncology - September 22nd, 2021
- Stem Rx Bioscience Solutions successfully use cell-based therapy for age-related macular degeneration and restoration of vision - Financial Express - September 22nd, 2021
- Repeated injury to the epithelial tissue of airways causes "biological aging" of stem cells - News-Medical.net - September 22nd, 2021
- Revival of the cell and gene therapy field opens new avenues for repairing the Parkinsonian brain - News-Medical.Net - September 22nd, 2021
- Scientists Awarded The Albany Prize, America's Most Distinguished Prize in Medicine, for Research Leading to Covid-19 Vaccines - Albany Medical Center - September 22nd, 2021
- Why I Believe It Is Wrong To Take The COVID Vaccine - And Response - The Chattanoogan - September 22nd, 2021
- How can fertility counseling be implemented for every newly diagnosed pediatric patient facing gonadotoxic ... - Physician's Weekly - September 20th, 2021
- Mantle Cell Lymphoma Treatment in the Era of COVID-19 - Curetoday.com - September 20th, 2021
- Calloway County Health Department announces 23 new cases of COVID-19 - Murray Ledger and Times - September 20th, 2021
- Effects of Leukemia on Your Body - Healthline - September 20th, 2021
- DCGI approves stem cell-based therapy trial for COVID-19 pneumonia treatment - BSI bureau - September 17th, 2021
- Dr. Anderson on the Challenges Faced With CAR T-Cell Therapy in Myeloma - OncLive - September 17th, 2021
- Treatment Methods: Transplant Eligibility in R/R DLBCL and CAR T Cell Therapy - Targeted Oncology - September 17th, 2021
- Insights into the cellular and molecular changes in male infertility - EurekAlert - September 17th, 2021
- Loss of Vision Caused by AMD: Cell-Based Therapy Can Help Restore Your Eyesight - TheHealthSite - September 17th, 2021
- The Promise of Regenerative Medicine to Treat Chronic Pain - Newswise - September 17th, 2021
- Researchers build the ovarian environment using mouse stem cells - News-Medical.net - September 17th, 2021
- Molecular and Cellular Changes in the Testicular Tissue of Infertile Men Revealed - Technology Networks - September 17th, 2021
- Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial - Yahoo Finance - September 17th, 2021
- Indolent lymphoma: Symptoms, outlook, treatment, and more - Medical News Today - September 17th, 2021
- Dr. Shah on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma - OncLive - September 17th, 2021
- Researchers focus on improving biomaterials used for bone and tissue repair - News-Medical.net - September 17th, 2021
- Dr. Kahl on Patient Selection for Intensive Vs Non-Intensive Treatment in MCL - OncLive - September 17th, 2021
- Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and ... - The Bakersfield Californian - September 14th, 2021
- Meet the Finnish team using stem cells to cure blindness - Sifted - September 14th, 2021
- Why you should feel optimistic about the future of healthcare - Say - Say Communications - September 14th, 2021
- Treating Hearing Loss: The Hunt for Drugs That Promote Hair Cell Regeneration - Technology Networks - September 14th, 2021
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and... - September 14th, 2021
- Celebrating the End of Cancer Treatment - Curetoday.com - September 14th, 2021
- BlueCross Will Cover Costs for COVID-19 Booster - Business Wire - September 14th, 2021
- UAB opening vaccination sites in Hoover and Ensley - UAB News - September 12th, 2021
- CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021 - Yahoo Finance - September 10th, 2021
- A Knee or Hip Replacement Without Surgery? Its on the Horizon - The Wall Street Journal - September 10th, 2021
- Jerry Nelson: Stem cell treatment can be alternative to joint replacement - Watertown Public Opinion - September 10th, 2021
- Graft Vs Host Prophylaxis With Posttransplant Cyclophosphamide Not Associated With Increased Infection Risk - Hematology Advisor - September 10th, 2021
- Carolina Researchers Lead CZI Collaborative on Childhood Diseases | Newsroom - UNC Health and UNC School of Medicine - September 10th, 2021
- A New Opportunity To Receive Sight - mvprogress - September 8th, 2021
- Japan: A case study of national readiness for regenerative medicine - Open Access Government - September 8th, 2021
- Merger Proposals Blocked By Cell Therapies Developer - Labmate Online - September 8th, 2021
- Using Predictive, Data Analytics to Expand Knowledge of Alzheimer's - HealthITAnalytics.com - September 8th, 2021
- Research on preterm brain injury treatment recognised - Medicine, Nursing and Health Sciences - Monash University - September 8th, 2021
- Roche bets $300M on Adaptimmune tech for off-the-shelf cell therapies for cancer - MedCity News - September 8th, 2021
- Desperate family have just three weeks to find stem cell donor for their girl - Express - September 8th, 2021
- Ivy Tech nursing student among 234 who want religious exemption to vaccine mandate - The Indianapolis Star - September 8th, 2021
- Convection Improves Survival and Insulin Secretion of Beta Cell Implants - Genetic Engineering & Biotechnology News - September 8th, 2021
- Bone Therapeutics reports half year 2021 results - GlobeNewswire - September 8th, 2021
- How a Family's Persistence Led to Their Son's Successful Sickle Cell TreatmentWith the Help of My Special Aflac Duck EBONY - EBONY - September 8th, 2021
- Leukemia Awareness Month: Changing the Future of AML through Precision Medicine - Targeted Oncology - September 8th, 2021
- Third Line Therapies in R/R FL - Cancer Network - September 8th, 2021
- BMS opts-in on Evotec's neurodegenerative medicine - PharmaTimes - September 7th, 2021
- New Cancer Treatments May Be on The Horizon Thanks to Success in mRNA Vaccine Trial - Good News Network - September 7th, 2021
- Billionaires Have Reportedly Invested In A BioTech Company Aiming To Reverse Aging - IFLScience - September 7th, 2021
- Human Mini-Lungs Grown in Lab Dishes are Closest Yet to Real Thing - UC San Diego Health - September 1st, 2021
- Targeting and inhibiting a protein could provide more effective treatment for brain cancer - News-Medical.Net - September 1st, 2021
- Could gene therapies be used to cure more people with HIV? - aidsmap - September 1st, 2021
- BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - Yahoo Finance - September 1st, 2021
- Future Therapeutic Options for Diffuse Large B-Cell Lymphoma - Targeted Oncology - September 1st, 2021
- COVID-19 Causes Severe Disease, Disrupted Treatment in Children with Cancer - Pharmacy Times - September 1st, 2021
- Blood cancer and its impact on female fertility - Lexology - September 1st, 2021
- New gene therapies may soon treat dozens of rare diseases, but million-dollar price tags will put them out of reach for many - The Conversation US - September 1st, 2021
- Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking... - August 30th, 2021
- Bengaluru boy with rare disease meets his German stem cell donor - The Hans India - August 30th, 2021
- Novartis falls behind rivals in race to bring CAR-T to early lymphoma - BioPharma Dive - August 30th, 2021
- Mike Tysons weird stem cell treatment has helped transform incredible body at 55 - Daily Star - August 28th, 2021
- University of Miami Researchers Enter Phase 3 of Stem Cell Clinical Trial in Treating COVID-19 Acute Respiratory Distress Syndrome - Newswise - August 28th, 2021
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... - August 28th, 2021
- College of Medicine University of Central Florida Research Wounds Heal Faster with New Treatment: Military Medicine Discovery - PRNewswire - August 28th, 2021
- Lab-grown minibrains with eyes may advance personalized drug testing, researchers say - Mahoning Matters - August 28th, 2021
- Off-the-Shelf NK Cell Products FT596 and FT516 Show Early Promise in B-cell Lymphoma - OncLive - August 28th, 2021
- BioMarin stands tall with first approved drug for rare disease that causes dwarfism - MedCity News - August 28th, 2021
- What to know about the third COVID-19 shot in Gainesville, Alachua County - Gainesville Sun - August 28th, 2021
- Department of Public Health Offering Third Dose COVID-19 Vaccines to Eligible Individuals | Monroe County, NY - monroecounty.gov - August 28th, 2021
- Cell Culture Protein Surface Coating Market | Know the Diverse Growth Parameters Influencing the Market - BioSpace - August 23rd, 2021
- County providing COVID-19 third dose booster to immunocompromised - City of Fort Worth - August 23rd, 2021
- Outcomes For MCL Patients and Impact of Relapse Timing After Transplant on OS - Targeted Oncology - August 23rd, 2021
- SGMC Offering COVID-19 Third Dose to Immunocompromised People - sgmc.org - August 23rd, 2021